title: Intermittent hormonal therapy for prostate cancer.
abstract: OBJECTIVE
  Intermittent hormonal therapy (IHT) for prostate cancer aims to minimize treatment-related side-effects, to improve overall quality of life, to reduce the cost of care, and possibly to delay progression to castration-resistant prostate cancer.
  
  
  RESULTS
  With preclinical evidence suggesting a potential benefit for IHT in terms of time to androgen independence, with phase II and phase III studies producing optimistic results, and with the potential for reductions in cost and complications, IHT has become a popular modality of therapy around the globe.
  
  
  CONCLUSIONS
  In the near future intermittent therapy will have place in the treatment strategy in the management of prostate cancer, particularly on men with locally advanced disease.
authors.affiliation: Grupo Português Genito-Urinário, Lisbon, Portugal. calais@seug-gpgu.com
authors.forename: Fernando Calais
authors.initials: FC
authors.lastname: da Silva
mesh_terms: D000728:Androgens / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D017430:Prostate-Specific Antigen